of treatment. Patients treated with TUR-B followed by radiotherapy were significantly older compared to patients with cystectomy before radiotherapy and were less likely to receive chemotherapy. There was no significant difference for the length of the interval between first treatment and radiotherapy for the three groups. Despite of this, type of surgical procedure before radiotherapy did not show an impact on overall survival (p = 0.86).

Conclusion: In our study we found equal survival of patients treated with (chemo)radiotherapy after TUR-B only compared to patients with cystectomy prior to radiotherapy. Younger age and more concomitant chemotherapy of the latter group was not able to prolong survival.

EP-1389
Stereotactic radiotherapy for oligometastatic patients with renal cell carcinoma
A. Cecconi1,2, G. Piperno1, A. Ferrari1, E. Rondi4, S. Vigorito4, D. Zerini3, F. Cattani4, F. Nolè5, O. De Cobelli2,6, B.A. Jereczek-Fossa2,3, R. Orecchia1,2
1European Institute of Oncology, Scientific Direction, Milan, Italy
2University of Milan, University of Milan, Milan, Italy
3European Institute of Oncology, Oncology, Milan, Italy
4European Institute of Oncology, Medical Physics, Milan, Italy
5European Institute of Oncology, Division of urogenital tumours medical treatment, Milan, Italy
6European Institute of Oncology, Division of urologic surgery, Milan, Italy

Purpose or Objective: the aim of this study was the evaluation of local control (LC) and toxicity in oligometastatic patients with renal cell carcinoma (RCC) who had undergone stereotactic radiotherapy (SRT) with CyberKnife (Accuray, Sunnyvale, CA) or Vero® (BrainLab) for cranial and extracranial metastases.

Material and Methods: between January 2012 and September 2015, 23 patients (30 lesions) with metastases of RCC were treated with SRT alone to the new site of disease (if limited disease) or to residual disease during the maximal response in systemic therapy. Disease control was evaluated with serial imaging. Toxicity was recorded according to the Common Toxicity Criteria version 4.0.

Results: after a median follow-up of 10 months (range 0 - 36 months) 20 patients were alive. Ten patients received SRT alone and 13 patients received that during the maximal response in systemic therapy. The median equivalent of the dose (EQPD) was 50.6 Gy delivered with a median of 2.7 fractions (range 1-5) and the median biological equivalent dose (BED) was 51 Gy assuming α/β =10 for tumour. Six patients are lost in follow-up. Clinical and radiological response was thus evaluated in 17 patients and the their LC was 100% (57.1% of patients received SRT alone and the others patients are still undergoing systemic treatment. 27.7% of patients had more than 12 months follow-up and the LC was again 100%). Progression of disease in the other sites was observed in all cases. No toxicity was observed.

Conclusion: SRT is a feasible approach that offer an excellent LC with low toxicity profile in the treatment management of oligometastatic patients with RCC with or without the association of systemic therapy. Further investigation is warranted to identify the patients who would probably benefit from this approach.
University of Naples "Federico II", Department of Biomedical Sciences Advanced, Naples, Italy
CNR, Institute of Biostructures and Bioimaging, Naples, Italy

Purpose or Objective: Acute urinary unwhised effects of pelvic irradiation may impact on quality of life of patients undergoing radiation therapy on the pelvis. Neoplasms such as endometrial, cervical, rectal, and anal cancer requires irradiation of relevant pelvic volumes. In this study we tested Cystoman, a dietary integrator of D-mannosium, cranberry and vitamin C, as prophylactic therapy for the development of acute urinary side effects.

Material and Methods: Fifty five patients undergoing pelvic irradiation were randomly assigned to take 2 tablets/day of Cystoman or not from the beginning of radiation therapy. Radiation therapy consisted of 45 - 50.4 Gy on the pelvis given by 1.8 Gy daily fractions with 3D conformal radiation therapy. The patients were weekly checked for urinary symptoms. Urine culture was performed before and after the treatment.

Results: Between November 2014 and September 2015, 55 consecutive patients were enrolled in the study. Median age was 65 years, 11 were affected by cervical cancer, 9 endometrial, 31 rectal, and 4 anal cancer. Twenty two patients were treated preoperatively and 33 postoperatively. Urinary toxicity appeared at the second week in 3/28 patients in Cystoman group and 11/27 in the control group (p=0.02). However by the end of the treatment 8/28 and 13/27 patients had urinary toxicity in the Cystoman and control group, respectively (p=0.1).

Conclusion: Our study suggests that Cystoman delays the radio-induced acute urinary toxicity presentation and could ameliorate the toxicity profile of the pelvic irradiation.

Electronic Poster: Clinical track: Skin cancer / malignant melanoma

EP-1391
Total skin irradiation using helical tomotherapy: a novel experience and report of three cases
University of Tokyo Hospital, Radiology, Tokyo, Japan
University of Tokyo Hospital, Dermatology, Tokyo, Japan

Purpose or Objective: Description of three cases of total skin irradiation for cutaneous T-cell lymphoma using helical TomoTherapy (Accuray, Sunnyvale, CA).

Material and Methods: In 2015, three patients with refractory T-cell lymphoma underwent total skin irradiation using invers-planned helical tomotherapy. The first case was a 25-year-old man diagnosed as mycosis fungoides with multiple tumors occurring on the extremities, face, and trunk. The second case was a 73-year-old woman diagnosed as primary cutaneous gamma delta T-cell lymphoma. She had received 24 Gy of irradiation in 12 fractions with total skin electron beam irradiation technique 10 years ago, and some parts of her skin were irradiated with 24 Gy in 12 fractions with local electron beam irradiation within 3 years. The third case was a 52-year-old man diagnosed as mycosis fungoides. No bolus was added around the body. Because of the long length of treatment of the body in TomoTherapy, treatments were delivered to three parts of the body (trunk, head and neck, and legs). Irradiation was not performed in two or three parts on the same day. Each plan was generated with a prescription dose of 10 Gy in 10 fractions. The planning target volume (PTV) was the body surface with 5mm margins of internal and external lesions of the skin. The third patient had several swelling lymph nodes, so the PTV was the body surface and swollen lymph nodes with their margins.

Results: TomoTherapy technique was created that enabled delivery of the prescription dose to PTV with a relatively sharp drop-off of dose at depth. The calculated mean doses for the organs at risk were 1.96, 2.08, 2.12, 2.19, and 2.27 Gy for the lung, heart, liver, kidneys, and bones, respectively. Using the couch-indexed Vac-Lok cushion and head mask, inter- and intra-fractional patients motions were minimized. All three patients experienced edemas of fingers and toes, and lost much of their hair. Myelosuppression occurred in two of the three patients. Because of grade 4 myelosuppression, the second patient who was treated total skin electron beam irradiation 10 years ago, was treated with blood transfusion during the treatment. All tumors were reduced during and after the treatment.

Conclusion: Using the TomoTherapy technique in total skin irradiation, we were able to achieve good coverage of the PTV and good sparing of organs at risk, including the bones. This treatment method, including the prescription dose and treatment duration, will be needed further research.

EP-1392
The abscopal effect: efficacy of radiotherapy in patients on progression after ipilimumab 3 mg/kg
Istituto Nazionale Tumori Fondazione Pascale, Melanoma-Cancer Immunotherapy and Innovative Therapy Unit, Naples, Italy
Regina Elena National Cancer Institute, Statistical Unit, Rome, Italy
Istituto Nazionale Tumori Fondazione Pascale, Radiotherapy, Naples, Italy
Istituto Nazionale Tumori Fondazione Pascale, Radiology, Naples, Italy
National Research Council, research, Sassari, Italy
Istituto Nazionale Tumori Fondazione Pascale, Scientific Direction, Naples, Italy

Purpose or Objective: After more than 30 years, Ipilimumab was the first agent which showed a survival benefit for the treatment of metastatic melanoma. However, only about the 20% of patients have a long-term survival benefit. The combination of ipilimumab with other therapies might improve its efficacy. Abscopal effect refers to a regression of metastatic lesions distant from the primary site of radiotherapy (RT). This systemic response is observed in patients who received ipilimumab. Here we reported the outcomes from patients treated in the ipilimumab Italian expanded access program (EAP) who received RT after ipilimumab progression.

Material and Methods: Patients with advanced melanoma who had received RT after ipilimumab progression were eligible for analysis. Radiotherapy was available upon physician request for patients who failed ipilimumab therapy and for whom no other therapeutic options were available.

Results: 21 out of 95 patients treated with ipilimumab in the Italian EAP were eligible for the analysis. The median age was of 58 years (range 21-77); the progression free survival (PFS) from ipilimumab treatment was 4 months (range 3-6), while the time from the end of treatment with ipilimumab and RT was of 5 months (range 4-8). RT was performed on brain in 13 patients: 8 were treated with whole-brain RT and 5 patients with stereotactic RT. Other RT treatment included bone, metastatic distant lymph nodes, sub-cutaneous metastasis, spinal cord metastasis. The median doses was 30 Gy (range 30-50). A local response to RT was detected in 13 patients while 8 patients did not show any local regression. The abscopal response has been detected in 11/21 patients: in details, we observed 9 abscopal partial response, 2 abscopal stable disease, and 10 progression. The median of occurrence of the abscopal response was of 1 month (range 1-4). The median overall survival (OS) for all the 21 patients was of 13 months (range 6-26). The median OS for patients